Navigation Links
DOS47 in Medical Technology

Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

...ment.tau.ac.il/meeting-2007.html">http://cancermicroenvironment.tau.ac.il/meeting-2007.html About L-DOS47 L-DOS47 combines Helix's proprietary dos47 new drug candidate with a highly specific single domain antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of...
DOS47 in Biological Technology

Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference

...ce, please visit http://www.aapspharmaceutica.com/meetings/biotec/bt09/index.asp . About L-DOS47 L-DOS47 combines Helix's proprietary dos47 new drug candidate with a highly specific single domain antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of...

Helix BioPharma to Present at the BioFinance 2009 Conference

... EDT on Wednesday, April 29, at The Toronto Marriott in Toronto. Mr. Docherty will provide an overview of the company's leading technology platforms, dos47 and Biphasix(TM), and its current product development programs, L-DOS47 and Topical Interferon Alpha-2b. The slide show portion of the presentation w...

Helix BioPharma Corp. Announces Fiscal 2008 Results

...or 23.0% when compared to fiscal 2007. Both Topical Interferon Alpha-2b and dos47 reflect an increase of 20.6% and 25.0%, respectively. The increase in dos47 research and development expenditures reflect advancing preclinical costs i...

Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canada's Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada

... Genomics and Health Initiative conference, please visit: http://www.pbi.nrc.ca/ghi-agm.htm . About L-DOS47 L-DOS47 combines Helix's proprietary dos47 new drug candidate with a highly specific single domain antibody, to form a potential new targeted drug product for the treatment of adenocarcinoma of...

Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format

...ividual vials may be reconstituted in liquid form immediately prior to patient administration." About L-DOS47 L-DOS47 combines Helix's proprietary dos47 new drug candidate with a highly specific single domain antibody to form a potential new targeted drug product for the treatment of adenocarcinoma of ...
Other Tags
(Date:8/3/2015)... ... 03, 2015 , ... Bayer has agreed to pay $56.9 million to set ... claimant alleged to have suffered an arterial blood clot including stroke and heart attack. ... and Ocella, has been ongoing for well-over five years. In 2009, lawsuits filed against ...
(Date:8/3/2015)... ... 2015 , ... BESLER Consulting today announced the firm has ... MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative work ... their Readmissions Analytics product was selected as one of four finalists in the ...
(Date:8/3/2015)... UK (PRWEB) , ... August 03, 2015 , ... ... R&D services to contract research organisations (CROs) for a slew of benefits, allowing ... global research and operations, boost quality with cost-effective utilisation of resources, get access ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... that while an overwhelming number of Hispanics believe people can positively affect their ... percent of participants queried said making diet changes was important. Far fewer participants ...
(Date:8/3/2015)... , ... August 03, 2015 ... ... and fitness site and the largest online retailer of nutritional supplements, has ... Sports is up for 11 awards in the following categories:, ...
Breaking Medicine News(10 mins):Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new Match-in-Sensor™ ... hardware encapsulated fingerprint sensor and matching solution. ... literally off the grid, isolating fingerprint image ... the fingerprint sensor to provide ultimate protection ...
Breaking Biology News(10 mins):Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 2Synaptics Announces World's First Match-in-Sensor Fingerprint Authentication Technology 3
Other Contents